Company overview
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing DRMA with another company.
| Daily close (USD) | $1.02 |
| Market capitalization (USD) | $4,102,585.86 |
| Price / earnings (TTM) | Not reported |
| Price / book | 1.18 |
No matching rows. Clear the filter to see all records.
Read DRMA's valuation metrics
Company size
Dermata Therapeutics, Inc. Common Stock's recorded market capitalization is $4,102,585.86. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
DRMA's recorded price-to-book ratio is 1.18. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Dermata Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about DRMA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow DRMA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.